Evogene (TSE:EVGN – Get Free Report) had its price objective lowered by Pi Financial from C$5.00 to C$4.00 in a report released on Wednesday, BayStreet.CA reports.
Evogene Stock Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Read More
- Five stocks we like better than Evogene
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Hasbro’s Management Made All the Right Calls This Quarter
- There Are Different Types of Stock To Invest In
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- NYSE Stocks Give Investors a Variety of Quality Options
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.